2026 Annual Public Meeting of the Board of Directors

July 21, 2026
2:30pm (eastern)

 

Each year, the Reagan-Udall Foundation for the FDA’s Board of Directors conducts an annual public meeting to highlight our activities in support of the U.S. Food and Drug Administration. The meeting provides an opportunity for engagement among the Foundation’s Board of Directors, FDA, and external stakeholders, including patients and consumers, regulated industry, health care providers, academics, and others dedicated to improving America’s health.

Our 2026 meeting will feature insights and Agency priorities from Acting FDA Commissioner Kyle Diamantas, FDA Chief Scientist Steven Kozlowski, and Acting FDA Chief of Staff Lowell Zeta.


The meeting will also include updates on the Foundation’s impact with Board Chair Adrian F. Hernandez, MD, MHS; Board Directors David C. Fajgenbaum, MD, MBA, Esther Krofah, MPP, and Phuong Khanh (PK) Morrow, MD; and CEO Susan C. Winckler, RPh, Esq.


This is a hybrid event. In-person registration is currently full. Please register to attend virtually and email admin@reaganudall.org to be added to the in-person waitlist.

Agenda

2:30pm (eastern) start

Welcome & Call to Order

  • Adrian F. Hernandez, MD, MHS 
    Board Chair, Reagan-Udall Foundation for the FDA

Year in Review

  • Adrian F. Hernandez, MD, MHS
  • Susan C. Winckler, RPh, Esq.
    Chief Executive Officer, Reagan-Udall Foundation for the FDA

The Year Ahead: Strategic & Scientific Priorities

  • Steven Kozlowski, MD
    Chief Scientist, U.S. Food and Drug Administration
  • Lowell Zeta, JD
    Acting Chief of Staff, Deputy Commissioner for Strategic Initiatives, and Special Counsel, U.S. Food and Drug Administration

Exploring the Foundation's Impact

A discussion with members of the Foundation's Board of Directors

  • David C. Fajgenbaum, MD, MBA, MSc, FCPP
  • Adrian F. Hernandez, MD, MHS
  • Esther Krofah, MPP
  • Phuong Khanh (PK) Morrow, MD

Remarks from the Acting Commissioner

  • Kyle Diamantas, JD
    Acting Commissioner of Food and Drugs, U.S. Food and Drug Administration

Closing Remarks & Adjourn

  • Susan C. Winckler, RPh, Esq.

Past Annual Public Meetings